Navigation Links
Mayo Clinic researchers identify new enzyme to fight Alzheimer's disease
Date:9/17/2012

JACKSONVILLE, Fla. An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme known as BACE2 destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease. The findings were published online Sept. 17 in the science journal Molecular Neurodegeneration.

Alzheimer's disease is the most common memory disorder. It affects more that 5.5 million people in the United States. Despite the disorder's enormous financial and personal toll, effective treatments have not yet been found.

The Mayo research team, led by Malcolm A. Leissring, Ph.D., a neuroscientist at Mayo Clinic in Florida, made the discovery by testing hundreds of enzymes for the ability to lower beta-amyloid levels. BACE2 was found to lower beta-amyloid more effectively than all other enzymes tested. The discovery is interesting because BACE2 is closely related to another enzyme, known as BACE1, involved in producing beta-amyloid.

"Despite their close similarity, the two enzymes have completely opposite effects on beta-amyloid BACE1 giveth, while BACE2 taketh away," Dr. Leissring says.

Beta-amyloid is a fragment of a larger protein, known as APP, and is produced by enzymes that cut APP at two places. BACE1 is the enzyme responsible for making the first cut that generates beta-amyloid. The research showed that BACE2 cuts beta-amyloid into smaller pieces, thereby destroying it, instead. Although other enzymes are known to break down beta-amyloid, BACE2 is particularly efficient at this function, the study found.

Previous work had shown that BACE2 can also lower beta-amyloid levels by a second mechanism: by cutting APP at a different spot from BACE1. BACE2 cuts in the middle of the beta-amyloid portion, which prevents beta-amyloid production.

"The fact that BACE2 can lower beta-amyloid by two distinct mechanisms makes this enzyme an especially attractive candidate for gene therapy to treat Alzheimer's disease," says first author Samer Abdul-Hay, Ph.D., a neuroscientist at Mayo Clinic in Florida.

The discovery suggests that impairments in BACE2 might increase the risk of Alzheimer's disease. This is important because certain drugs in clinical use for example, antiviral drugs used to treat human immunodeficiency virus (HIV) work by inhibiting enzymes similar to BACE2.

Although BACE2 can lower beta-amyloid by two distinct mechanisms, only the newly discovered mechanism beta-amyloid destruction is likely relevant to the disease, the researchers note. This is because the second mechanism, which involves BACE2 cutting APP, does not occur in the brain. The researchers have obtained a grant from the National Institutes of Health to study whether blocking beta-amyloid destruction by BACE2 can increase the risk for Alzheimer's disease in a mouse model of the disease.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Clinic-based community program helps with childhood obesity
2. PARP inhibitors may have clinical utility in HER2-positive breast cancers
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. New national clinical trials network for neurological disorders to foster cutting-edge treatments
5. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
6. Epigenetics emerges powerfully as a clinical tool
7. Mayo Clinic suicide prevention expert outlines new steps to tackle military suicide
8. Physicians empathy directly associated with positive clinical outcomes, confirms large study
9. When clinicians and researchers look outside the box
10. Suicide prevention, telemedicine among topics at Mayo Clinic Transform 2012
11. Joint EACPR and AHA statement empowers health care professional to use Clinical Cardiopulmonary Exercise Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino ... its network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo ... flail mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers ...
(Date:3/29/2017)... ... ... Full Contact K9, an Atlanta-based dog services provider, has recently teamed up with ... in creating legally-enforceable pet trusts for their canine companions. , Therilus, a Harvard-trained ... new companion. Says Evan Dunbar, CEO of Full Contact K9, “When our clients purchase ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... Indianapolis, IN (PRWEB) , ... March 29, 2017 ... ... Benefits Study, this webinar provides insight into the challenges employers face in trying ... the complexity of managing employee benefits programs? Adding to the growing complexity, ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... DUBLIN , Mar 30, 2017 ... "Hemodialysis And Peritoneal Dialysis Market Size & Forecast, By Type ... (Home-based, Hospital-based), And Trend Analysis From 2014 To 2025" ... ... market is expected to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... March 29, 2017 Wound care devices and ... of the wound. The industry mainly consists of establishments ... the treatment of wounds caused by mechanical, chemical, thermal, ... diseases such as diabetes, skin related diseases, immunological diseases, ... was the largest region in the wound ...
(Date:3/29/2017)... 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused company ... announced that Carmine N. Stengone , president and chief executive ... & Company 16 th Annual Healthcare Conference on Wednesday, April ... Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology: